Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.

P Whiting, Maiwenn Al, LT (Laura) Burgers, M Westwood, S Ryder, Martine Hoogendoorn - Lips, N Armstrong, A Allen, Hans Severens, J Kleijnen

Research output: Contribution to journalArticleAcademicpeer-review

73 Citations (Scopus)
Original languageUndefined/Unknown
JournalHealth Technology Assessment
Volume18
Issue number8
DOIs
Publication statusPublished - 2014
Externally publishedYes

Cite this